Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6016277 | Epilepsy Research | 2009 | 4 Pages |
Abstract
A cohort of patients attending a tertiary referral centre for epilepsy was identified as having started taking PGB. Patients' data were obtained through medical records. Of 402 patients included, 42% of patients were still taking PGB at last follow-up. The estimated 2.5-year retention rate was 32%. Males appeared more likely to continue on PGB therapy than females. The common adverse experiences (AEs) leading to withdrawal were CNS-related, psychiatric AEs and weight gain. Published retention rates for levetiracetam appear to be higher, and those for gabapentin lower, than the rates estimated for PGB.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Alan W.C. Yuen, Rinki Singh, Gail S. Bell, Anupam Bhattacharjee, Aidan Neligan, Dominic C. Heaney, John S. Duncan, Josemir W. Sander,